Zhengye Biotechnology Holding (ZYBT) Current Assets (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Current Assets for 3 consecutive years, with $19.4 million the latest figure, recorded in Q4 2025.

• Quarterly Current Assets fell 21.62% year-over-year to $19.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.4 million (down 21.62% YoY) and the FY2025 annual result came in at $19.6 million, down 19.23% from the prior year.
• Current Assets slipped to $19.4 million in Q4 2025 per ZYBT's latest filing, from $28.1 million in the prior quarter.
• Over the last five years, Current Assets for ZYBT reached as high as $28.1 million in Q2 2025 and fell as low as $19.4 million in Q4 2025.
• A 3-year average of $24.6 million and a median of $25.5 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets decreased 5.95% — and 2025, when it declined 21.62%.
• Year by year, Current Assets stood at $26.3 million in 2023, then dropped by 5.95% to $24.7 million in 2024, then declined by 21.62% to $19.4 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $19.4 million, $28.1 million, and $24.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.